Academic and non-commercial research
Access EvE Bio's dataset through DrugBank's open-science program for academic or non-commercial use. Ideal for universities, research institutes, and non-profit projects.
Request academic accessMapping the global network of drug-protein interactions
EvE Bio is now integrated into DrugBank, creating the largest public resource of drug–protein interactions and making off-target biology searchable, connected, and actionable for the first time.
Off-target interactions now accessible at scale
Most approved drugs interact with dozens, sometimes hundreds, of proteins beyond their intended target. These off-target interactions drive side effects, adherence issues, and treatment discontinuation, but have been measured in scattered experiments.
When mapped systematically, they allow researchers to re-evaluate clinical observations, uncover the mechanisms behind adverse events, and identify new therapeutic opportunities grounded in biology.
- 385,572
- Drug-protein combinations
- 159
- Targets
- 1,397
- Compounds
Explore EvE Bio's pharmome
EvE Bio measured how approved small molecules interact with major target classes including GPCRs, kinases, and nuclear receptors.
- Method: Each interaction is tested using standardized biochemical and cell-based assays to distinguish true actives from non-specific or frequent hitters.
- Connected: Integrated into DrugBank's Knowledge Graph, this data connects binding activity to pathways, diseases, and clinical trials.
Number of drug-protein interactions with drugs grouped by indicated therapeutic area. Counted across EvE Bio and DrugBank together.
The interaction map is drawn in your browser from the published dataset.
0
0
From data to discovery
Safety triage for approved drugs
A new adverse event emerges in post-market surveillance. Pull the drug's interaction profile across receptor classes, review quantified activity alongside cell-viability data, and pinpoint potential molecular drivers.
By connecting these results to pathways, diseases, and trials, DrugBank helps teams generate mechanistic hypotheses and plan follow-up validation faster.
Repurposing candidate identification
Which approved drugs show activity at your target of interest? Filter for agonists or antagonists within EvE Bio's screened targets, exclude compounds with cytotoxic signals, and prioritize by selectivity.
Results highlight drugs with known safety profiles and relevant activity — ideal starting points for proof-of-concept studies or repositioning campaigns.
Mechanistic hypothesis generation
When a drug shows an unexpected effect or safety signal, explore its off-target interaction profile to identify which receptors may be responsible.
By linking those targets to pathways, diseases, and known outcomes, researchers can generate testable hypotheses about underlying mechanisms and guide smarter clinical or preclinical investigations.
About EvE Bio
EvE Bio is a focused research organization (FRO) on a mission to map the pharmome — the complete network of interactions between approved drugs and human proteins.
Through systematic, high-throughput experimental screening, EvE Bio generates validated drug-target interaction data, and releases it publicly under a Creative Commons license.
Data access and licensing
Advanced research and data integration
Access EvE Bio's full dataset within DrugBank's knowledge graph. Query across drugs, targets, and trials, export structured data, and integrate results into your analytics or discovery pipelines.
Contact SalesFrequently asked questions
How can my organization partner or integrate with DrugBank?
Email us at partnerships@drugbank.com to explore integration and commercial licensing options.
How is the data generated?
EvE Bio uses standardized assays (β-arrestin, TR-FRET) across GPCRs, kinases, and nuclear receptors. Results include potency metrics (pXC50) and quality flags for frequent hitters and cytotoxic effects.
Can I use this data commercially?
Yes. Commercial licensing is available through EvE Bio and DrugBank for enterprise or AI/ML model training applications.